TrialRMD open2024

Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupus erythematosus.

Yoshiya Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.